Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor

被引：0
|
作者：
Cascino, TL
Veeder, MH
Buckner, JC
OFallon, JR
Wiesenfeld, M
Levitt, R
Goldberg, RM
Kuross, SA
Morton, RF
Scheithauer, BW
机构：
[1] ILLINOIS ONCOL RES ASSOC,COMMUNITY CLIN ONCOL PROGRAM,PEORIA,IL 61602
[2] CEDAR RAPIDS ONCOL PROJECT,CCOP,CEDAR RAPIDS,IA 52403
[3] MERITCARE HOSP,CCOP,FARGO,ND 58123
[4] GEISINGER CLIN ONCOL PROGRAM,DANVILLE,PA 17822
[5] DULUTH COMMUNITY CLIN ONCOL PROGRAM,DULUTH,MN 55805
[6] IOWA ONCOL RES ASSOC,CCOP,DES MOINES,IA 50314
来源：
JOURNAL OF NEURO-ONCOLOGY | 1996年 / 30卷 / 03期
关键词：
recurrent glioma; 5-fluorouracil; leucovorin; radiation therapy; astrocytoma; oligodendroglioma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Thirty patients with recurrent primary brain tumors were treated with a combination of 5-fluorouracil and leucovorin. There were three responses seen. Toxicity consisted of stomatitis, diarrhea, and hematological suppression. 5-fluorouracil and leucovorin would appear to be minimally effective in recurrent brain tumors.
引用
收藏
页码：243 / 246
页数：4
相关论文
共 50 条
  • [21] A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma
    Blanke, CD
    Haller, DG
    Benson, AB
    Rothenberg, ML
    Berlin, J
    Mori, M
    Hsieh, YC
    Miller, LL
    ANNALS OF ONCOLOGY, 2001, 12 (11) : 1575 - 1580
  • [22] Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer
    Kono, T
    Ebisawa, Y
    Tomita, I
    Chisato, N
    Kamiya, K
    Asama, T
    Ayabe, T
    Ashida, T
    Kohgo, Y
    Kasai, S
    JOURNAL OF CHEMOTHERAPY, 2005, 17 (02) : 224 - 227
  • [23] A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors
    Jordan D. Berlin
    Dona B. Alberti
    Rhoda Z. Arzoomanian
    Chris A. Feierabend
    Kris J. Simon
    Kim A. Binger
    Rebecca M. Marnocha
    George Wilding
    Investigational New Drugs, 1998, 16 : 325 - 330
  • [24] A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and or metastatic solid tumors
    Berlin, JD
    Alberti, DB
    Arzoomanian, RZ
    Feierabend, CA
    Simon, KJ
    Binger, KA
    Marnocha, RM
    Wilding, G
    INVESTIGATIONAL NEW DRUGS, 1999, 16 (04) : 325 - 330
  • [25] A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma
    Morgan-Meadows, S
    Mulkerin, D
    Berlin, JD
    Kim, K
    Bailey, H
    Saphner, T
    Jumonville, A
    Hansen, R
    Ahuja, H
    McFarland, T
    Thomas, JP
    ONCOLOGY, 2005, 69 (02) : 130 - 134
  • [26] Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: A phase II study
    Raderer, M
    Kornek, GV
    Hejna, MH
    Weinlaender, G
    Vorbeck, F
    Fiebiger, WCC
    Scheithauer, W
    ANNALS OF ONCOLOGY, 1997, 8 (08) : 797 - 799
  • [27] 5-FLUOROURACIL PLUS LEUCOVORIN IN WOMEN WITH METASTATIC BREAST-CANCER - A PHASE-II STUDY
    LOPRINZI, CL
    INGLE, JN
    SCHAID, DJ
    BUCKNER, JC
    EDMONSON, JH
    ALLEGRA, CJ
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (01): : 30 - 32
  • [28] Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer
    Chiou, TJ
    Tung, SL
    Hsieh, RK
    Wang, WS
    Yen, CC
    Fan, FS
    Liu, JH
    Chen, PM
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1998, 28 (05) : 318 - 322
  • [29] A PHASE-II TRIAL OF 5-FLUOROURACIL AND HIGH-DOSE LEUCOVORIN IN RECURRENT EPITHELIAL OVARIAN-CARCINOMA
    LOOK, KY
    MUSS, HB
    BLESSING, JA
    MORRIS, M
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (01): : 19 - 22
  • [30] Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil, and leucovorin versus oxaliplatin, 5-fluorouracil, and leucovorin versus 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG E3201-An updated survival analysis.
    Nimeiri, Halla Sayed
    Feng, Yang
    Catalano, Paul J.
    Meropol, Neal J.
    Giantonio, Bruce J.
    Sigurdson, Elin R.
    Martenson, James A.
    Whitehead, Robert P.
    Sinicrope, Frank A.
    Mayer, Robert J.
    O'Dwyer, Peter J.
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345